Advertisement
U.S. markets closed

Novus Acquisition & Development Corp. (NDEV)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0185-0.0017 (-8.64%)
At close: 12:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0203
Open0.0185
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0185 - 0.0185
52 Week Range0.0112 - 0.0380
Volume5,055
Avg. Volume17,276
Market Cap1.994M
Beta (5Y Monthly)-0.38
PE Ratio (TTM)18.50
EPS (TTM)0.0010
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NDEV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NOVUS ACQUISITION & DEVELOPMENT
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    16 hours agoArgus Research
View more
  • PR Newswire

    Branded Legacy and Novus Partner to Develop Plant-Based Meds for Health Plans

    Branded Legacy, Inc (OTC.PK: BLEG), an emerging biotechnology company, is excited to announce a strategic partnership with Novus Acquisition & Development Corp (OTC.PK: NDEV), a national supplemental health insurance carrier that is a pioneer in offering cannabis-embedded health plans for both recreational and medical use. This collaboration marks a significant milestone in Branded Legacy's mission to revolutionize the biotechnology landscape while creating a profound impact on the healthcare in

  • ACCESSWIRE

    Novus Releases Its First Quarter Financial Statements For 2023

    Novus Acquisition and Development, Corp. (OTC Markets:NDEV), through its wholly-owned subsidiary WCIG Insurance Services, Inc. Operates as a national supplemental health insurance carrier and, the nation's first health carrier offering cannabis that is included in health plans for recreational and medicinal users.